Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Return on Assets (2016 - 2023)

Endonovo Therapeutics has reported Return on Assets over the past 10 years, most recently at 4.81% for Q3 2023.

  • Quarterly results put Return on Assets at 4.81% for Q3 2023, down 275.0% from a year ago — trailing twelve months through Sep 2023 was 4.81% (down 275.0% YoY), and the annual figure for FY2022 was 11.24%, down 989.0%.
  • Return on Assets for Q3 2023 was 4.81% at Endonovo Therapeutics, down from 3.83% in the prior quarter.
  • Over the last five years, Return on Assets for ENDV hit a ceiling of 0.15% in Q4 2020 and a floor of 13.52% in Q4 2022.
  • Median Return on Assets over the past 5 years was 2.89% (2021), compared with a mean of 3.48%.
  • Biggest five-year swings in Return on Assets: surged 503bps in 2020 and later crashed -1202bps in 2022.
  • Endonovo Therapeutics' Return on Assets stood at 5.18% in 2019, then skyrocketed by 97bps to 0.15% in 2020, then tumbled by -911bps to 1.5% in 2021, then crashed by -802bps to 13.52% in 2022, then soared by 64bps to 4.81% in 2023.
  • The last three reported values for Return on Assets were 4.81% (Q3 2023), 3.83% (Q2 2023), and 7.12% (Q1 2023) per Business Quant data.